🧠 “Reproducibility is the key challenge in science, and now we have a first validation of the results. These findings confirm that ExoPTEN has the potential impact of a true therapeutic.” — Prof. Michael Belkin, Scientific Advisor to NurExone 📢 In collaboration with the Goldschleger Eye Institute at Sheba Medical Center, Tel Hashomer, we have made another breakthrough step toward addressing vision loss in patients with optic nerve damage, such as glaucoma and related conditions. Our lead candidate ExoPTEN demonstrated reproducible, dose-dependent restoration of visual function after optic nerve injury in a new preclinical study. Ygal Rotenstreich Ifat Sher #Exosomes #RegenerativeMedicine #Glaucoma #VisionRestoration #NurExone #ExoPTEN #Neuroregeneration #Biotech Read More: https://lnkd.in/dseC5wc2
NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
Biotechnology Research
Regenerate - Rewire - Recover
About us
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
- Website
-
https://nurexone.com
External link for NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Haifa
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Get directions
Haifa, IL
Employees at NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
-
Yossi Mograbi
-
Shulamit Levenberg
Professor at The Technion- Israel Institute of Technology
-
Sharon Soueid-Baumgarten
Senior Scientist at NurExone Biologic
-
Lior Shaltiel, PhD
Chief Executive Officer at NurExone Biologic (TSXV:NRX)(OTCQB:NRXBF)(FSE:J90) | Senior Lecturer (of the practice) Head of the BioMed-MBA program at…
Updates
-
NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) reposted this
🌟 Breaking Barriers in Regenerative Medicine: Dr. Tali Kizhner’s Vision for Exosome-Based Therapies 🌟 How can exosomes revolutionise the treatment of central nervous system injuries? Tali Kizhner, Research and Development Director of NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90), is leading the charge with ExoPTEN—a groundbreaking drug candidate designed to enable true neural repair and functional recovery in spinal cord injuries. In this exclusive interview, Dr. Kizhner shares: ✅ NurExone’s bold mission to harness exosomes for targeted siRNA delivery. ✅ The biggest hurdles in translating EV therapies to clinical success. ✅ How AI and advanced technologies could shape the future of exosome development. 💡 “We are trying something very new and bold, with strong preclinical results. This could be a real breakthrough for millions of lives.” – Dr. Tali Kizhner 👉 Read the full interview here: https://lnkd.in/eWNn8jE6 📅 Join us at Exosomes Europe in Amsterdam to hear Dr. Kizhner’s presentation and connect with the brightest minds in EV therapies. 🔗 Register now: https://lnkd.in/dYNYAsCd #ExosomesEurope #RegenerativeMedicine #ExosomeTherapies
-
-
Proprietary Production...Patents...Private Placement...and more... Watch here! Thanks Stockhouse! Thanks Ricki Lee! https://lnkd.in/g37HwvRj
NurExone Secures Key Patents, Prepares for Major US Uplisting | CEO Interview
https://www.youtube.com/
-
Well said Lior Shaltiel, PhD!!
Chief Executive Officer at NurExone Biologic (TSXV:NRX)(OTCQB:NRXBF)(FSE:J90) | Senior Lecturer (of the practice) Head of the BioMed-MBA program at HUJI
From Startup Nation to Biotech Nation Patients around the world 🌍 benefit from Israeli biotech every day as breakthrough therapies, devices, and diagnostics born here 🐣 improve and save lives 🧬. Now it’s time to scale and invest. We have everything we need—scientists, talent, and resources—to become a true Biotech Nation. It’s up to us to recognize that strength and build on it 💡. Read more in my recent op-ed (Hebrew) in Calcalist - A leading Israeli business and innovation newspaper https://lnkd.in/dm75TkCb #BiotechNation #StartupNation #IsraelInnovation #LifeSciences
-
Q. Why Indiana? A. Because it’s #1 in U.S. life-sciences exports (2024) and generates $99 B in annual economic output. That’s why NurExone is planning to establish our first GMP exosome manufacturing facility in Indianapolis, Indiana. 🙏 Thank you to Indiana Secretary of Commerce David Adams and the Indiana Office of Commerce for the incentive offer and for the opportunity to join the state’s thriving life-sciences ecosystem. https://lnkd.in/dMXV_4dE #Exosomes #RegenerativeMedicine #Biotech #Indiana #Manufacturing #NurExone #Growth #LifeSciences
-
-
💡Three corporate updates: ✅ Israel Patent Grant – Expanding global IP coverage alongside a recent U.S. Notice of Allowance. ✅ Private Placement Closed – Funds raised to advance our preclinical pipeline and U.S. manufacturing plans. ✅ U.S. Conference Presence – Showcasing ExoPTEN at industry events in Boston this month (BioProcess International, Exosome-Based Therapeutic Development Summit) #Biotech #Boston #Exosomes #RegenerativeMedicine #NurExone #ExoPTEN Read more: https://lnkd.in/dKPxzKmB
-
-
💡 Zacks Small Cap Research just published a coverage update, maintaining their $3.50/share valuation vs. our current $0.61. 🔒 The report underscores the strength of our IP moat and scalable exosome manufacturing process. 📊 It also highlights the multi-market potential of ExoPTEN to generate diverse revenue streams. Read more: https://lnkd.in/dkV68yAP
-
-
🔬✨ In biotech, IP is a great moat!! Strong patents are what protect biotech efforts, give investors confidence, and secure a sustainable path to market. So we’re proud that we received a U.S. Patent Allowance for our proprietary process of producing exosomes! Together with our GMP-grade Master Cell Bank, this milestone reinforces our supply chain readiness and strengthens our path toward first-in-human trials. #Biotech #IP #Exosomes #RegenerativeMedicine #Innovation https://lnkd.in/dSfwausg
-